Literature DB >> 33821390

Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility.

Marialuisa Sponziello1, Giuseppe Damante2, Catia Mio3, Antonella Verrienti1, Valeria Pecce1.   

Abstract

BACKGROUND: Understanding the molecular mechanisms underlying papillary thyroid cancer (PTC) proved to be vital not only for diagnostic purposes but also for tailored treatments. Despite the strong evidence of heritability, only a small subset of alterations has been implicated in PTC pathogenesis. To this reason, we used targeted next-generation sequencing (NGS) to identify candidate variants implicated in PTC pathogenesis, progression, and invasiveness.
METHODS: A total of 42 primary PTC tissues were investigated using a targeted next-generation sequencing (NGS) panel enlisting 47 genes involved in DNA repair and tumor progression.
RESULTS: We identified 57 point mutations in 78.5% of samples (n = 32). Thirty-two somatic mutations were identified exclusively in known thyroid cancer genes (BRAF, KRAS, NRAS, and TERT). Unpredictably, 45% of the all identified mutations (n = 25) resulted to be germline, most affecting DNA repair genes. Interestingly, none of the latter variants was in the main population databases. Following ACMG classification, 20% of pathogenic/likely pathogenic and 68% of variant of unknown significance were identified.
CONCLUSIONS: Overall, our results support the hypothesis that rare germline variants in DNA repair genes are accountable for PTC susceptibility. More data, including the segregation analysis in affected families, should be collected before definitely annotate these alterations and to establish their potential prognostic and treatment implications.
© 2021. The Author(s).

Entities:  

Keywords:  DNA repair; Germline variants; Next-generation sequencing; Papillary thyroid cancer

Year:  2021        PMID: 33821390     DOI: 10.1007/s12020-021-02705-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  17 in total

1.  Assessing thyroid cancer risk using polygenic risk scores.

Authors:  Sandya Liyanarachchi; Julius Gudmundsson; Egil Ferkingstad; Huiling He; Jon G Jonasson; Vinicius Tragante; Folkert W Asselbergs; Li Xu; Lambertus A Kiemeney; Romana T Netea-Maier; Jose I Mayordomo; Theo S Plantinga; Hannes Hjartarson; Jon Hrafnkelsson; Erich M Sturgis; Pamela Brock; Fadi Nabhan; Gudmar Thorleifsson; Matthew D Ringel; Kari Stefansson; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-04       Impact factor: 11.205

2.  Diabetes. 1.

Authors:  A R Holder
Journal:  JAMA       Date:  1973-01-22       Impact factor: 56.272

Review 3.  BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.

Authors:  Ralph P Tufano; Gilberto V Teixeira; Justin Bishop; Kathryn A Carson; Mingzhao Xing
Journal:  Medicine (Baltimore)       Date:  2012-09       Impact factor: 1.889

4.  Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway.

Authors:  Marta Codrich; Marina Comelli; Matilde Clarissa Malfatti; Catia Mio; Dilara Ayyildiz; Chi Zhang; Mark R Kelley; Giovanni Terrosu; Carlo E M Pucillo; Gianluca Tell
Journal:  DNA Repair (Amst)       Date:  2019-08-07

5.  Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.

Authors:  Jaroslaw Jendrzejewski; Sandya Liyanarachchi; Rebecca Nagy; Leigha Senter; Paul E Wakely; Andrew Thomas; Fadi Nabhan; Huiling He; Wei Li; Krzysztof Sworczak; Matthew D Ringel; Lawrence S Kirschner; Albert de la Chapelle
Journal:  Thyroid       Date:  2016-07-22       Impact factor: 6.568

6.  A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2.

Authors:  Antonella Verrienti; Antonella Carbone; Pasquale Bellitti; Maria Chiara Fabiano; Roberta F De Rose; Marianna Maranghi; Piernatale Lucia; Cosimo Durante; Francesca Rosignolo; Valeria Pecce; Marialuisa Sponziello; Cinzia Puppin; Giuseppe Costante; Rocco Bruno
Journal:  Endocr Pract       Date:  2015-08-06       Impact factor: 3.443

7.  Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study.

Authors:  Ilir Agalliu; Miia Suuriniemi; Ludmila Prokunina-Olsson; Bo Johanneson; Francis S Collins; Janet L Stanford; Elaine A Ostrander
Journal:  Prostate       Date:  2008-05-15       Impact factor: 4.104

8.  Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.

Authors:  Rengyun Liu; Justin Bishop; Guangwu Zhu; Tao Zhang; Paul W Ladenson; Mingzhao Xing
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

9.  Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer.

Authors:  Jungnam Joo; Kyong-Ah Yoon; Tomonori Hayashi; Sun-Young Kong; Hye-Jin Shin; Boram Park; Young Min Kim; Sang-Hyun Hwang; Jeongseon Kim; Aesun Shin; Joo-Young Kim
Journal:  Cancer Res Treat       Date:  2015-06-22       Impact factor: 4.679

10.  Identification of tumorigenesis-related mRNAs associated with RNA-binding protein HuR in thyroid cancer cells.

Authors:  Federica Baldan; Catia Mio; Lorenzo Allegri; Ketty Conzatti; Barbara Toffoletto; Cinzia Puppin; Slobodanka Radovic; Carlo Vascotto; Diego Russo; Carla Di Loreto; Giuseppe Damante
Journal:  Oncotarget       Date:  2016-09-27
View more
  1 in total

1.  PMS2 variant results in loss of ATPase activity without compromising mismatch repair.

Authors:  Brandon M D'Arcy; Jennifer Arrington; Justin Weisman; Steven B McClellan; Zhengrong Yang; Champion Deivanayagam; Jessa Blount; Aishwarya Prakash
Journal:  Mol Genet Genomic Med       Date:  2022-02-21       Impact factor: 2.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.